What is Nectar Lifesciences Ltd (NECLIFE) share price return in the past 10 years?

Nectar Lifesciences Ltd share price has declined -10.3% annually (CAGR) over the past ten years.

What is the share price of Nectar Lifesciences Ltd (NECLIFE)?

Company share prices are keep on changing according to the market conditions. The current trading price of Nectar Lifesciences Ltd (NECLIFE) on 10-Jun-2026 11:54:00 at 11:54 is 11.63.

What is the P/E ratio of Nectar Lifesciences?

The latest standalone P/E ratio of Nectar Lifesciences as of 10-Jun-2026 is 0.00.

What is the P/B ratio of Nectar Lifesciences Ltd (NECLIFE)?

The latest standalone P/B ratio of Nectar Lifesciences Ltd (NECLIFE) as of 10-Jun-2026 is 0.39.

What is the 52-week high and low of Nectar Lifesciences Ltd (NECLIFE)?

The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is Rs. 25.53 and the 52-week low is Rs. 9.20.

Nectar Lifesciences Ltd (NECLIFE) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Nectar Lifesciences Ltd (NECLIFE)
Brand: Nectar Lifesciences

Nectar Lifesciences Ltd (NECLIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532649 NSE: NECLIFE Pharmaceuticals & Drugs | Small Cap | Nectar Lifesciences Share Price

Nectar Lifesciences Ltd (NECLIFE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532649 NSE: NECLIFE Pharmaceuticals & Drugs | Small Cap | Nectar Lifesciences Share Price

Key Metrics

Valuation Multiples

Market Cap

₹228 Cr.

Current Price

₹11.6

52-Week Low / High

₹9 / 26

TTM EPS

₹-3

TTM Sales

₹0 Cr.

Book Value per Share

₹30

P/E Ratio

0.00

Industry PE

Price to Book (P/B)

0.39

Lower than its 5-year historical median

Price to Sales (P/S)

0.00

Lower than its 5-year historical median

EV/EBITDA

-2.34

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

-11.23%

Underperforms industry median

Return on Capital Employed (ROCE)

-4.68%

Underperforms industry median

Return on Assets (ROA)

-5.44%

Operating Profit Margin

-1.8%

Net Profit Margin

-6.81%

Gross Profit Margin

-5.2%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-0.84%

Operating Profit Growth (1 Year)

-119.5%

Net Profit Growth (1 Year)

-2373.6%

Asset Quality

Promoter Holding

51.84%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹823 Cr.

Equity

₹19.4 Cr.

Face Value

₹1

All Time Low / High

₹7.20 / 60.90

Nectar Lifesciences stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Somewhat Overvalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Nectar Lifesciences Ltd a good quality company?

Nectar Lifesciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Nectar Lifesciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Nectar Lifesciences Ltd vs industry peers?

Nectar Lifesciences Ltd revenue CAGR is -6.71%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Nectar Lifesciences Ltd?

Promoters hold 51.84% of the Nectar Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Nectar Lifesciences Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -10.8% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	10%	9.7%	9.1%	10.3%	8.2%	1.4%	5.8%	2.6%	6.7%	-4.7%	-
Value Creation Index ⓘ	-0.3	-0.3	-0.4	-0.3	-0.4	-0.9	-0.6	-0.8	-0.5	-1.3	-
Growth Parameters ⓘ
Sales ⓘ	1,676	1,643	1,876	2,785	2,363	1,542	1,668	1,524	1,684	1,670	0
Sales YoY Gr.	-	-2%	14.1%	48.5%	-15.2%	-34.8%	8.2%	-8.7%	10.5%	-0.8%	-
Adj EPS ⓘ	2.4	2.4	2.3	2.1	1.3	-2.5	0.8	-2.6	-0.1	-5.3	-3
YoY Gr.	-	-0.4%	-3.7%	-9%	-37.3%	-285.7%	NA	-406%	NA	NA	-
BVPS (₹) ⓘ	42.6	44.9	47.2	49.3	50.6	47.3	48.5	47.5	47.7	42.6	30
Adj Net Profit ⓘ	54.4	54.3	52.2	47.5	29.9	-55.4	18.7	-57.7	-2	-120	-57
Cash Flow from Ops. ⓘ	169	199	65.1	239	286	21.3	95	133	225	169	-
Debt/CF from Ops. ⓘ	5.7	4.4	14.7	3.8	2.7	42.4	9.1	5.7	2.8	3.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-0%	-6.7%	0%	-0.8%
Adj EPS ⓘ	-209.1%	-232.1%	-285.3%	NA
BVPSⓘ	0%	-3.4%	-4.2%	-10.6%
Share Price	-10.3%	-21.1%	-12.8%	-49.7%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	5.7	5.5	5.1	4.4	2.7	-5	1.7	-5.4	-0.2	-11.8	-8.1
Op. Profit Mgn % ⓘ	14.3	13.6	12.6	9.5	9.2	6.6	9.5	3.6	9	-1.8	-21.8
Net Profit Mgn % ⓘ	3.3	3.3	2.8	1.7	1.3	-3.6	1.1	-3.8	-0.1	-7.2	-INF
Debt to Equity ⓘ	1	0.9	0.9	0.8	0.7	0.9	0.8	0.7	0.6	0.6	0
Working Cap Days ⓘ	298	324	292	206	240	330	288	310	272	262	1,166
Cash Conv. Cycle ⓘ	142	153	133	104	115	132	108	126	109	111	-2,043

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1,676	1,643	1,876	2,785	2,363	1,542	1,668	1,524	1,684	1,670
Operating Expenses ⓘ +	1,437	1,419	1,639	2,521	2,145	1,440	1,509	1,469	1,533	1,700
Manufacturing Costs	127	129	145	154	140	129	147	173	186	164
Material Costs	1,175	1,154	1,366	2,221	1,858	1,156	1,222	1,159	1,202	1,368
Employee Cost	78	76	75	77	78	71	72	75	82	94
Other Costs ⓘ	57	61	54	69	69	85	68	62	63	74
Operating Profit ⓘ	239	224	236	264	218	102	159	55	152	-30
Operating Profit Margin (%)	14.2%	13.6%	12.6%	9.5%	9.2%	6.6%	9.5%	3.6%	9.0%	-1.8%
Other Income ⓘ +	6	23	6	6	4	11	11	53	27	16
Exceptional Items ⓘ	0	0	0	0	0	-25	0	0	0	0
Interest ⓘ	123	117	115	148	126	112	79	89	99	86
Depreciation ⓘ	57	62	64	63	61	60	57	59	61	62
Profit Before Tax ⓘ	64	67	63	59	36	-85	34	-41	18	-162
Tax ⓘ	10	12	10	11	6	-12	9	-18	13	-48
Profit After Tax	54	55	52	47	30	-73	25	-22	5	-114
PAT Margin (%)	3.2%	3.4%	2.8%	1.7%	1.3%	-4.7%	1.5%	-1.5%	0.3%	-6.8%
Adjusted EPS (₹)	2.4	2.5	2.3	2.1	1.3	-3.3	1.1	-1.0	0.2	-5.1
Dividend Payout Ratio (%)	4.10%	2%	2.20%	2.40%	3.70%	0%	0%	0%	0%	0%

Valuation of Nectar Lifesciences - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	954	1,007	1,059	1,105	1,135	1,061	1,087	1,065	1,069	956
Share Capital ⓘ	22	22	22	22	22	22	22	22	22	22
Reserves ⓘ	932	984	1,036	1,082	1,112	1,038	1,064	1,042	1,047	934
Debt +	873	794	854	802	741	840	794	685	553	500
Long Term Debt	245	164	220	166	121	128	291	226	140	60
Short Term Debt	627	630	634	636	620	712	503	459	412	440
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	497	528	539	483	527	342	377	319	420	438
Others Liabilities ⓘ	233	252	272	315	229	132	130	100	142	98
Total Liabilities ⓘ	2,557	2,581	2,724	2,704	2,632	2,375	2,387	2,169	2,184	1,992
Fixed Assets
Net Fixed Assets ⓘ +	906	881	852	825	785	772	723	662	643	633
Gross Block	1,384	1,364	1,456	1,490	1,509	1,556	1,563	1,558	1,599	1,652
Accumulated Depreciation	478	482	604	666	724	784	840	896	957	1,019
CWIP ⓘ	99	102	100	100	115	99	85	78	66	57
Investments ⓘ	1	1	1	1	1	1	1	1	1	1
Inventories	836	854	859	915	975	587	660	673	709	690
Trade Receivables	492	500	612	561	397	375	447	280	379	345
Cash Equivalents	36	13	9	21	21	25	18	18	20	19
Others Assets ⓘ	186	229	290	282	338	516	454	459	366	247
Total Assets ⓘ	2,557	2,581	2,724	2,704	2,632	2,375	2,387	2,169	2,184	1,992

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	169	199	65	239	286	21	95	133	225	169
PBT ⓘ	65	67	63	59	36	-85	34	-41	18	-162
Adjustment ⓘ	174	159	176	207	188	148	125	97	138	139
Changes in Working Capital ⓘ	-62	-20	-161	-13	72	-39	-65	77	69	192
Tax Paid ⓘ	-9	-7	-13	-14	-9	-4	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-77	-18	-29	-26	-33	-29	17	52	-17	-42
Capex	-82	-25	-33	-36	-36	-31	15	50	-29	-44
Net Investments	-1	0	-0	0	0	-0	0	1	0	0
Others ⓘ	6	7	3	10	3	3	2	2	12	2
Cash Flow From Financing Activity ⓘ +	-89	-204	-40	-201	-252	11	-119	-186	-205	-128
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	5	-87	73	-53	-108	32	166	-62	-72	-82
Interest Paid ⓘ	-123	-117	-115	-148	-126	-112	-79	-79	-87	-75
Dividend Paid ⓘ	-3	-3	-1	-1	-1	-1	0	0	0	0
Others ⓘ	32	3	4	2	-16	92	-206	-44	-47	28
Net Cash Flow ⓘ	3	-24	-4	12	1	4	-8	-0	2	-1

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	5.79	5.62	5.05	4.38	2.68	-6.66	2.36	-2.09	0.47	-11.23
ROCE (%)	9.95	9.71	9.12	10.28	8.24	1.41	5.79	2.58	6.68	-4.68
Asset Turnover Ratio	0.71	0.68	0.79	1.15	0.99	0.7	0.81	0.77	0.88	0.91
PAT to CFO Conversion(x)	3.13	3.62	1.25	5.09	9.53	N/A	3.8	N/A	45	N/A
Working Capital Days
Receivable Days	95.50	103.90	97	68.80	66.30	79.90	77.90	75.90	62.40	69.30
Inventory Days	165.60	176.90	149.50	103.90	130.70	161.80	118.20	139.20	130.90	133.80
Payable Days	148	162.10	142.60	84	99.20	137.30	107.30	109.50	112.10	114.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

100.00

99.60

98.77

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Nectar Lifesciences Ltd FAQs

The current trading price of Nectar Lifesciences on 10-Jun-2026 11:54 is ₹11.63.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2026 the market cap of Nectar Lifesciences stood at ₹228.3 Cr

The latest P/E ratio of Nectar Lifesciences as of 09-Jun-2026 is 0.00.

The latest P/B ratio of Nectar Lifesciences as of 09-Jun-2026 is 0.39.

The 52-week high of Nectar Lifesciences is ₹25.53 and the 52-week low is ₹9.20.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹0.00 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.

The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Nectar Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Nectar Lifesciences Ltd

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Business segments

APIs
Formulations
Empty hard Gelatin Capsules
Phytochemicals

Certifications

GMP (Issued by World Health Organization - COPP)
ISO 9001:2008 - Quality Management
ISO 22000:2005 - Food Safety Management
ISO 14001: 2004 - Environment Management Systems
ISO 50001: 2011 - Energy Management System
OHSAS 18001: 2007 - Occupational Health and Safety

Nectar Lifesciences Ltd (NECLIFE)

Nectar Lifesciences Ltd (NECLIFE)

Nectar Lifesciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Nectar Lifesciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Nectar Lifesciences Ltd FAQs

About Nectar Lifesciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Nectar Lifesciences Ltd (NECLIFE)

Nectar Lifesciences Ltd (NECLIFE)

Nectar Lifesciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Nectar Lifesciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Nectar Lifesciences Ltd FAQs

What is the share price of Nectar Lifesciences?

What is the market cap of Nectar Lifesciences?

What is the P/E ratio of Nectar Lifesciences?

What is the P/B ratio of Nectar Lifesciences?

What is the 52-week high and low of Nectar Lifesciences?

What is the TTM revenue of Nectar Lifesciences?

Is Nectar Lifesciences Ltd a good quality company?

Is Nectar Lifesciences Ltd undervalued or overvalued?

Is Nectar Lifesciences Ltd a good buy now?

About Nectar Lifesciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.